Callan Capital LLC Acquires 68 Shares of Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,510 shares of the company’s stock after purchasing an additional 68 shares during the quarter. Callan Capital LLC’s holdings in Zoetis were worth $425,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC grew its position in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the last quarter. Webster Bank N. A. increased its position in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares in the last quarter. Independence Bank of Kentucky raised its stake in Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Private Wealth Management Group LLC acquired a new stake in Zoetis in the fourth quarter worth about $33,000. Finally, Ramirez Asset Management Inc. purchased a new stake in shares of Zoetis during the third quarter worth about $35,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS traded down $0.75 during trading hours on Wednesday, hitting $173.49. The stock had a trading volume of 1,957,332 shares, compared to its average volume of 2,907,115. The firm has a 50-day moving average price of $171.62 and a 200 day moving average price of $177.52. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market capitalization of $79.16 billion, a price-to-earnings ratio of 33.34, a PEG ratio of 2.72 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the firm posted $1.31 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is presently 33.14%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZTS. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group lowered their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Stifel Nicolaus cut their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Finally, Barclays dropped their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.